Osimertinib as adjuvant therapy in patients with resected EGFRm stage IB-IIIA NSCLC: updated results from ADAURA

被引：0
|
作者：
Grohe, C. [1 ]
Tsuboi, M. [2 ]
Wu, Y. [3 ,4 ]
John, T. [5 ]
Majem, M. [6 ]
Wang, J. [7 ]
Kato, T. [8 ]
Goldman, J. [9 ]
Kim, S. [10 ]
Yu, C. [11 ,12 ]
Vu, H. [13 ]
Mukhametshina, G. [14 ]
Akewanlop, C. [15 ]
de Marinis, F. [16 ]
Shepherd, F. [17 ]
Urban, D. [18 ,19 ]
Stachowiak, M. [20 ]
Balanos, A. [20 ]
Huang, X. [20 ]
Herbst, R. [21 ,22 ]
Kern, J. [15 ,23 ]
机构：
[1] Evangel Lungenklin Berlin Buch, Berlin, Germany
[2] Natl Canc Ctr Hosp East, Kashiwa, Japan
[3] Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
[4] Guangdong Acad Med Sci, Guangzhou, Peoples R China
[5] Austin Hlth, Heidelberg, Australia
[6] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[7] Chinese Acad Med Sci, Beijing, Peoples R China
[8] Kanagawa Canc Ctr, Asahi Ward, Asahi, Japan
[9] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA
[10] Asan Med Ctr, Seoul, South Korea
[11] Natl Taiwan Univ Hosp, Taipei, Taiwan
[12] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[13] Cho Ray Hosp, Ho Chi Minh City, Vietnam
[14] Republican Clin Oncol Ctr, Kazan City, Russia
[15] Siriraj Hosp, Bangkok, Thailand
[16] IRCCS, European Inst Oncol Ieo, San Giovanni Rotondo, Italy
[17] Princess Margaret Canc Ctr, Univ Hlth Network, Toronto, ON, Canada
[18] Sheba Med Ctr, Tel Hashomer, Israel
[19] Sackler Fac Med, Tel Hashomer, Israel
[20] Astrazeneca, Cambridge, England
[21] Yale Sch Med, New Haven, CT USA
[22] Yale Canc Ctr, New Haven, CT USA
[23] Kwm Missio Clin, Wurzburg, Germany
来源：
PNEUMOLOGIE | 2023年 / 77卷
关键词：
D O I：
10.1055/s-0043-1760904
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
FV 96
引用
收藏
页码：S17 / S17
页数：1
相关论文
共 50 条
  • [31] Results of molecular pathological Studies (NGS) in curatively operated Patients with Stage IB-IIIA NSCLC
    Kurz, S.
    Olive, E.
    Zaatar, M.
    Leschber, G.
    Grohe, C.
    PNEUMOLOGIE, 2022, 76 : S79 - S79
  • [32] Biomarker testing and adjuvant osimertinib use in patients with resectable EGFR-mutated stage IB-IIIA NSCLC: Physician practices, therapy choice, and barriers among US oncologists
    Aggarwal, Puja
    Savill, Kristin M. Zimmerman
    Jeune-Smith, Yolaine
    Jennings-Zhang, Luke
    Bone, Robert
    Kelly, Ronan Joseph
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] HRQoL with Adjuvant Aumolertinib in Patients with Resected Stage IB-IIIA EGFR Mutant Non Small Cell Lung Cancer
    Hu, W.
    Mao, Z.
    Cheng, N.
    Huang, J.
    Tang, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S563 - S564
  • [34] Adjuvant Osimertinib in Resected EGFR-Mutated Stage IBeIIIA Non-Small Cell Lung Cancer: Updated ADAURA Results
    Herbst, R. S.
    Wu, Y. -L.
    Grohe, C.
    John, T.
    Majem, M.
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S. -W.
    Yu, C. -J.
    Vu, H. V.
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A.
    Huang, X.
    Tsuboi, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E4 - E4
  • [35] Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer
    Herbst, Roy S.
    John, Thomas
    Grohe, Christian
    Goldman, Jonathan W.
    Kato, Terufumi
    Laktionov, Konstantin
    Bonanno, Laura
    Tiseo, Marcello
    Majem, Margarita
    Domine, Manuel
    Ahn, Myung-Ju
    Kowalski, Dariusz M.
    Perol, Maurice
    Sriuranpong, Virote
    Ozguroglu, Mustafa
    Bhetariya, Preetida
    Markovets, Aleksandra
    Rukazenkov, Yuri
    Muldoon, Caitlin
    Robichaux, Jacqulyne
    Hartmaier, Ryan
    Tsuboi, Masahiro
    Wu, Yi-Long
    NATURE MEDICINE, 2025,
  • [36] MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC.
    Therasse, P.
    Vansteenkiste, J. F.
    Zielinski, M.
    De Pas, T. M.
    Atanackovic, D.
    Sequist, L. V.
    Vallieres, E.
    Swisher, S.
    Adams, S.
    Passlick, B.
    Eberhardt, W. E. E.
    Grunenwald, D.
    Mok, T.
    Boyer, M.
    Katz, A.
    Douillard, J.
    Debois, M.
    Brichard, V. G.
    Altorki, N. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] Real-world outcomes in resected stage IB-IIIA EGFR mutated NSCLC in Canada: Analysis from the POTENT study
    Kuruvilla, M. S.
    Syed, I.
    Gwadry-Sridhar, F.
    Sachdeva, R.
    Pencz, A.
    Zhan, L.
    Hueniken, K.
    Patel, D.
    Balaratnam, K.
    Khan, K.
    Grant, B.
    Sheffield, B.
    Noy, S.
    Singh, K. P.
    Liu, L.
    Ralibuz-Zaman, M.
    Davis, B.
    Moldaver, D.
    Shanahan, M.
    Cheema, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S931 - S932
  • [38] Prevalence, Treatment Patterns and Long-Term Clinical Outcomes of Patients with EGFR Positive Resected Stage IB-IIIA NSCLC
    Schmid, S.
    Garcia, M.
    Hueniken, K.
    Balaratnam, K.
    Patel, D.
    Zhan, L.
    Brown, M. C.
    Sacher, A.
    Bradbury, P.
    Leighl, N.
    Shepherd, F. A.
    Liu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S945 - S945
  • [39] Impact on Survival on Interval between Surgery and Adjuvant Chemotherapy in Completely Resected Stage IB-IIIA Lung Cancer
    Wang, Bing-Yen
    Huang, Jing-Yang
    Hung, Wei-Heng
    Lin, Ching-Hsiung
    Lin, Sheng-Hao
    Liaw, Yung-Po
    Ko, Jiunn-Liang
    PLOS ONE, 2016, 11 (11):
  • [40] Randomized Study of Adjuvant Docetaxel vs. Observation for Completely Resected Stage IB-IIIa NSCLC with 11 Years' Median Follow-Up
    Zhong, Wen-Zhao
    Yang, Xue-Ning
    Yan, Hong -Hong
    Liao, Ri-Qiang
    Nie, Qiang
    Dong, Song
    Jiang, Ben-Yuan
    Zhou, Qing
    Yang, Jin-Ji
    Wu, Yi Long
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S642 - S643
12345